SUPPLEMENT

Q1 2021 — Reconciliation of Non-GAAP Financial Measures

Q1 2021PDF · 4 pages144 KB
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2021 	2020
Net Earnings, after tax- as reported 	$6,197 	$5,796
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,215 	1,118
Litigation expense 	- 	120
Restructuring related 	104 	118
Acquisition, integration and divestiture related 1 	(538) 	(962)
Unrealized (gains)/losses on securities 	35 	327
Medical Device Regulation 	46 	14
Tax Adjustments
Tax impact on special item adjustments 2 	(113) 	(267)
Tax legislation and other tax related 	(22) 	(110)
Adjusted Net Earnings, after tax 	$6,924 	$6,154
Average shares outstanding (Diluted) 	2,672.7 	2,671.0
Adjusted net earnings per share (Diluted) 	$2.59 	$2.30
Operational adjusted net earnings per share (Diluted) 	$2.49
Notes:
1
2
First Quarter
Acquisition, integration and divestiture related for the first quarter of 2021 primarily includes the gain on the divestiture of 2
Pharmaeutical brands outside of the U.S. The first quarter of 2020 primarily includes a $983M Contingent Consideration reversal
related to the timing of certain developmental milestones associated with the Auris Health acquisition.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax
special items in arriving at adjusted earnings.

-- 1 of 4 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	(2.3)% 	9.6% 	10.9% 	7.9%
U.S. 	(7.4)% 	6.4% 	5.4% 	3.9%
International 	2.5% 	13.4% 	16.2% 	12.2%
WW Currency 	1.0 	2.5 	2.9 	2.4
U.S. 	- 	- 	- 	-
International 	2.0 	5.5 	5.7 	4.9
WW Operational 	(3.3)% 	7.1% 	8.0% 	5.5%
U.S. 	(7.4)% 	6.4% 	5.4% 	3.9%
International 	0.5% 	7.9% 	10.5% 	7.3%
General Surgery
Advanced Sterilization Products 	0.6 	0.2
U.S. 	0.0 	0.0
International 	1.2 	0.4
All Other Acquisitions and Divestitures 	0.4 	0.3 	0.1 	0.3
U.S. 	0.5 	(0.2) 	0.2 	0.0
International 	0.4 	0.9 	0.0 	0.5
WW Adjusted Operational 	(2.9)% 	7.4% 	8.8% 	6.0%
U.S. 	(6.9)% 	6.2% 	5.6% 	3.9%
International 	0.9% 	8.8% 	11.8% 	8.2%
Adjusted Operational Sales Growth
FIRST QUARTER 2021 ACTUAL vs. 2020 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 2 of 4 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020
Reported Income Before Tax by Segment 	$ 	788 	770 	5,223 	3,834 	1,629 	2,025 	(211) 	(120) 	7,429 	6,509
% to Sales 	22.2% 	21.2% 	42.8% 	34.4% 	24.8% 	34.1% 	-0.9% 	-0.6% 	33.3% 	31.5%
Intangible asset amortization 	106 	100 	856 	771 	253 	247 	- 	- 	1,215 	1,118
Litigation expense, net 	- 	- 	- 	93 	- 	27 	- 	- 	- 	120
Unrealized loss/(gain) on securities 	(2) 	1 	37 	314 	- 	12 	- 	- 	35 	327
Restructuring related 	28 	18 	20 	20 	56 	80 	- 	- 	104 	118
Acquisition, integration and divestiture related 	- 	- 	(570) 	9 	32 	(971) 	- 	- 	(538) 	(962)
Medical Device Regulation 	- 	- 	- 	- 	46 	14 	- 	- 	46 	14
Adjusted Income Before Tax by Segment 	$ 	920 	889 	5,566 	5,041 	2,016 	1,434 	(211) 	(120) 	8,291 	7,244
% to Sales 	26.0% 	24.5% 	45.6% 	45.3% 	30.6% 	24.2% 	-0.9% 	-0.6% 	37.1% 	35.0%
*Estimated as of 04/20/2021
Q1 YTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health 	Pharmaceutical 	Medical Devices 	Unallocated 	Worldwide Total

-- 3 of 4 --

First Quarter 	Acquistion, integration 	First Quarter
April 4, 2021
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
and divestiture
related (1)
Medical Device
Regulation
April 4, 2021
Non-GAAP
Cost of products sold 	7,063	$ 	(1,215) 	(27) 	(17) 	5,804
Selling, marketing and admin expenses 	5,432 	(5) 	5,427
Research and development expense 	3,178 	(24) 	3,154
Other (Income) / Expense 	(882) 	- 	- 	(24) 	538 	(35) 	(403)
Restructuring 	53 	(53) 	-
Provision for taxes on income 	1,232 	177 	- 	20 	(101) 	8 	9 	22 	1,367
Net Earnings 	6,197 	1,038 	- 	84 	(437) 	27 	37 	(22) 	6,924
First Quarter 	Acquistion, integration 	First Quarter
March 29, 2020
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
and divestiture
related (1)
Medical Device
Regulation
March 29, 2020
Non-GAAP
Cost of products sold 	7,062	$ 	(1,118) 	(15) 	(14) 	5,915
Other (Income) / Expense 	(679) 	(120) 	(45) 	962 	(327) 	(209)
Restructuring 	58 	(58) 	-
Provision for taxes on income 	713 	146 	20 	21 	3 	75 	2 	110 	1,090
Net Earnings 	5,796 	972 	100 	97 	(965) 	252 	12 	(110) 	6,154
Unrealized
(loss)/gain on
securities
Tax legislation
and other tax
related
(1) 2021 primarily includes gains on the divestiture of 2 Pharmaceutical brands outside of the United States. 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris
Health acquisition.
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Unrealized
(loss)/gain on
securities
Tax legislation
and other tax
related

-- 4 of 4 --